Hematology / Oncology CE Activities

Hematology / oncology blog

View Details

Targeting BCMA: A New Path in Relapsed/Refractory Multiple Myeloma

In triple- and quad-refractory myeloma, median survival was only about 9 months, and less than 6 months in penta-refractory disease.
View Details

Navigating Immunotherapy in Advanced NSCLC: What Every Oncologist Should Know

The advent of immunotherapy has significantly extended survival and revolutionized care in advanced non-small cell lung cancer (NSCLC).
View Details

Is Immunotherapy Right for Your Patient with Nonmelanoma Skin Cancer?

The primary goal of treatment in nonmelanoma skin cancer (NMSC) is tumor elimination with maximal preservation of function and cosmesis.

RMEI Presentations

RMEI DECISION SUPPORT AIDS

View Details

Intravitreal Anti-VEGF & Bispecific Therapies for DME & nAMD

In late 2022, the ocular implant, insertion tool assembly, (including the drug vial & initial fill needle) for ranibizumab PDS were voluntarily recalled due to septum dislodgement and paused implantations including ongoing global clinical trials; this did not include the refill vial and needle.
View Details

Cervical Cancer: What You Need to Know About Screening, Symptoms, and Treatments

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients. An estimated 13,960 women are diagnosed with invasive cervical cancer every year.
View Details

Seeing Nonmelanoma Skin Cancers Through A New Lens: The Role and Place of Immunotherapy

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients.
View Details

Relapsed or Refractory Chronic-Phase: CHRONIC MYELOID LEUKEMIA (CML)

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients.

LATEST HEMATOLOGY / ONCOLOGY ARTICLES

RSS Latest Hematology / Oncology Articles
  • ViPOR’s Venom — Rationally Targeting DLBCL with Precision June 20, 2024
    Large B-cell lymphoma (LBCL) spans the gamut of aggressive lymphoid tumors with extensive biologic and clinical heterogeneity. Most patients with LBCL are cured with the use of front-line chemoimmunotherapy, yet approximately 40% have a relapse.1 Although second-line CD19-targeted chimeric antigen receptor (CAR) T-cell therapy for persistent or early...
    Jordan S. Goldstein, Ash A. Alizadeh
  • Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma June 20, 2024
    In a phase 1b–2 study, a five-agent treatment aimed at tumor survival pathways in relapsed and refractory diffuse large B-cell lymphoma was associated with a complete response in 38% of the patients.
    Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, James D. Phelan, Da Wei Huang, George Wright, Jillian Simard, Jagan Muppidi, Craig J. Thomas, Michele Ceribelli, Frances A. Tosto, Yandan Yang, Weihong Xu, Theresa Davies-Hill, Svetlana D. Pack, Cody J. Peer, Oluwatobi Arisa, Esther Mena, Liza Lindenberg, Ethan Bergvall, Craig A. Portell, Rafic J. Farah, Seung Tae Lee, Amynah Pradhan, Candis Morrison, Atekelt Tadese, Anna Marie Juanitez, Crystal Lu, Allison Jacob, Heidi Simmons, William D. Figg, Seth M. Steinberg, Elaine S. Jaffe, Mark Roschewski, Louis M. Staudt, Wyndham H. Wilson
  • The Maternal Crossroad June 20, 2024
    When her mother is diagnosed with ovarian cancer, a young gynecologic oncologist finds herself at a difficult crossroads where physician, mother, daughter, and wife converge.
    Larissa H. Mattei

RMEI LIGHTNING TALKS

View Details

4 Years, 16 Live & Online Activities, 6000+ Clinicians: What we've learned so far

RMEI has released pairings of live and online programs approximately twice per year since 2016 grouped into “phases” which share clinical areas of focus and are based on findings from the previous phase of education. In total, 16 activities have launched to date with 4 activities currently live. The purpose of this analysis is to better understand the impact of multi-year iterative education on a clinical audience. Presented at: Society for Academic CME (SACME), virtual, February 2021; Accreditation Council for Continuing Medical Education (ACCME), virtual, April 2021.
View Details

Effectiveness of 5-year IBD Provider Online Educational Intervention Program

There is considerable practice variability among providers caring for inflammatory bowel disease (IBD) patients. Limited data exists on the effectiveness of educational interventions targeting IBD providers to address these gaps. We report outcomes for a 5-year provider education training program which culminated in an enduring online education resource and clinical decision support tool.